Nanomedicine Faces Persistent Obstacles in Cancer Gene Therapy

Strategic Insights -

Researchers at the University of Cambridge have identified key challenges facing nanomedicine in cancer treatment, highlighting the need for a re-examination of nanoparticle pharmacokinetics, optimization of dosing regimens, and solutions to antigen depletion to realize the full potential of nanomedicine. Despite recent advances in targeted drug delivery, clinical trials of nanoparticle-based systems have underperformed, leading to a call for a more effective approach.

Key Takeaways:

  • Recent advances in nanomedicine have improved delivery of small molecule therapies and biologics for cancer treatment, gene therapy, and vaccines, but clinical trials of targeted nanoparticle-based systems have underperformed.
  • The University of Cambridge research suggests that progress in nanomedicine will require a re-examination of nanoparticle pharmacokinetics, optimization of dosing regimens, and solutions to antigen depletion.
  • The researchers argue that these steps are critical for realising the full potential of nanomedicine and improving patient outcomes.
  • Financial support for the research came from the Engineering and Physical Sciences Research Council.
  • The research has been peer-reviewed and published in Materials Horizons in 2025.

Statistics:

  • The research was supported by the Engineering and Physical Sciences Research Council (EPSRC).
  • The publication "Reimagining drug nanocarriers: clinical realities and smarter strategies for targeted drug delivery" is available in Materials Horizons in 2025.
  • The United Kingdom is home to the University of Cambridge, where the research was conducted.
  • The research involved the development of targeted nanoparticle-based systems for cancer treatment.
  • The study highlights the need for a more effective approach to nanomedicine, including a re-examination of nanoparticle pharmacokinetics and optimization of dosing regimens.

Sources:

  • Materials Horizons, 2025
  • Royal Soc Chemistry, Thomas Graham House, Science Park, Milton Rd, Cambridge CB4 0WF, Cambs, England
  • Andrew George Baker, Dept. of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge, CB3 0AS, UK
  • Royal Soc Chemistry, Thomas Graham House, Science Park, Milton Rd, Cambridge CB4 0WF, Cambs, England